Valuation Cybin Inc.

Equities

Market Closed - Nyse Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
9.130 ^USD	+2.24%		+2.70%	+3.51%

Jan. 15	Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment	MT
Jan. 15	Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder	CI

Data adjusted to current consolidation scope

Fiscal Period: March	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	205.7	177	102.6	425.4	263.1	-	-
Change	-	-13.99%	-42.02%	314.65%	-38.16%	-	-
Enterprise Value (EV) ¹	141.7	123.3	85.96	216.7	151.9	258.8	-51.03
Change	-	-12.99%	-30.29%	152.09%	-29.91%	70.39%	-119.72%
P/E ratio	-4.1x	-2.55x	-2x	-2.24x	-2.7x	-2.06x	-3.99x
PBR	1.52x	2.24x	2x	0.6x	1.27x	2.58x	0.85x
PEG	-	-0.1x	0.1x	0.58x	0.1x	-0.1x	0.1x
Capitalization / Revenue	238x	-	-	-	-	-	1.04x
EV / Revenue	164x	-	-	-	-	-	-0.2x
EV / EBITDA	-7.39x	-2.7x	-1.85x	-2.76x	-1.25x	-2.51x	0.46x
EV / EBIT	-4.39x	-1.93x	-1.67x	-2.75x	-1.11x	-1.74x	0.43x
EV / FCF	-7.4x	-2.72x	-1.81x	-3.14x	-1.69x	-2.35x	7.28x
FCF Yield	-13.5%	-36.7%	-55.3%	-31.8%	-59.1%	-42.5%	13.7%
Dividend per Share ²	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-
EPS ²	-12.16	-15.2	-9.88	-9.5	-4.868	-6.37	-3.295
Distribution rate	-	-	-	-	-	-	-
Net sales ¹	0.864	-	-	-	-	-	252.9
EBITDA ¹	-19.17	-45.64	-46.58	-78.41	-121.4	-103.2	-109.8
EBIT ¹	-32.28	-63.84	-51.52	-78.84	-136.7	-148.6	-118
Net income ¹	-32.22	-67.63	-47.49	-78.08	-138.1	-170.4	-85.6
Net Debt ¹	-64.03	-53.64	-16.63	-208.7	-111.2	-4.3	-314.1
Reference price ²	49.86	38.76	19.79	21.26	13.15	13.15	13.15
Nbr of stocks (in thousands)	4,126	4,565	5,183	20,005	20,001	-	-
Announcement Date	6/28/21	6/22/22	6/27/23	6/26/24	-	-	-

¹CAD in Million²CAD

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield	Capi. ($)
CYBIN INC.	-2.7x	-	-1.25x	-	183M
VERTEX PHARMACEUTICALS INCORPORATED	-263.84x	9.14x	113.74x	-.--%	109B
REGENERON PHARMACEUTICALS, INC.	17.66x	4.47x	11.03x	-.--%	73.33B
ARGENX SE	484.34x	17.19x	-781.7x	-.--%	39.62B
BIONTECH SE	-32.85x	4.96x	-10.25x	-.--%	26.83B
BEIGENE, LTD.	-38.62x	5.55x	-39.22x	-.--%	22.39B
WUXI APPTEC CO., LTD.	16.22x	3.58x	10.24x	+1.86%	20.68B
NEUROCRINE BIOSCIENCES, INC.	35.62x	5.42x	20.34x	-.--%	14.5B
SUMMIT THERAPEUTICS INC.	-62.19x	-	-	-	14.03B
GENMAB A/S	17.99x	3.71x	11.49x	-.--%	13.23B
Average	17.16x	6.75x	-73.95x	+0.23%	33.35B
Weighted average by Cap.	-29.14x	7.71x	-57.28x	+0.12%